U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 34921 - 34930 of 34957 results

Status:
Investigational
Source:
Biomed Pharmacother. Sep 2013;67(7):659-63.: Not Applicable Human clinical trial Completed Dry Eye Syndromes
Source URL:

Class:
PROTEIN

Eledoisin is an endecapeptide tachykinin receptor ligand. Originally it was isolated from salivary glands of Mediterranean octopod, Eledone moschata. Eledoisin is a powerful vasodilator and hypotensive agent in most animal species.
Status:
US Previously Marketed
Source:
Acthar Gel synthetic by Armour
(1978)
Source URL:
First approved in 1978
Source:
Acthar Gel synthetic by Armour
Source URL:

Class:
PROTEIN

Seractide is a polypeptide hormone corresponding to thirty-nine amino acids of human corticotropin that differs from full-length human corticotropin at four positions. Seractide is potent endogenous melanocortin receptor 2 (MC ) agonist. Seractide stimulates the cortex of the adrenal gland and boosts the synthesis of corticosteroids, mainly glucocorticoids but also sex steroids (androgens). Seractide, was approved by FDA in 1978, but was never marketed. The Seractide, that was ultimately withdrawn by FDA in 2014 for safety reasons.
Status:
US Previously Marketed
Source:
Acthar Gel synthetic by Armour
(1978)
Source URL:
First approved in 1978
Source:
Acthar Gel synthetic by Armour
Source URL:

Class:
PROTEIN

Seractide is a polypeptide hormone corresponding to thirty-nine amino acids of human corticotropin that differs from full-length human corticotropin at four positions. Seractide is potent endogenous melanocortin receptor 2 (MC ) agonist. Seractide stimulates the cortex of the adrenal gland and boosts the synthesis of corticosteroids, mainly glucocorticoids but also sex steroids (androgens). Seractide, was approved by FDA in 1978, but was never marketed. The Seractide, that was ultimately withdrawn by FDA in 2014 for safety reasons.
YTTRIUM Y-90 (YTRACIS®, YTTRIGA®) is a radioactive form of the chemical element yttrium. It is used for radiolabelling other medicines. An example of its use is the treatment of some type of tumors, where the radiolabelled medicine carries the radioactivity to the site of a tumor to destroy the tumor cells.
nucleic acid
Status:
Investigational
Source:
NCT00017407: Phase 3 Interventional Completed Lung Cancer
(2000)
Source URL:

Class:
NUCLEIC ACID

Showing 34921 - 34930 of 34957 results